0001593968-24-000879.txt : 20240620 0001593968-24-000879.hdr.sgml : 20240620 20240620170839 ACCESSION NUMBER: 0001593968-24-000879 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240617 FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dubovsky Filip CENTRAL INDEX KEY: 0001977361 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26770 FILM NUMBER: 241057381 MAIL ADDRESS: STREET 1: C/O NOVAVAX INC. STREET 2: 21 FIRSTFIELD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NOVAVAX INC CENTRAL INDEX KEY: 0001000694 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 222816046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 700 QUINCE ORCHARD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 240-268-2000 MAIL ADDRESS: STREET 1: 700 QUINCE ORCHARD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 4 1 primary_01.xml PRIMARY DOCUMENT X0508 4 2024-06-17 0001000694 NOVAVAX INC NVAX 0001977361 Dubovsky Filip 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 true President, R&D false Common Stock 2024-06-17 4 M false 1404 6.97 A 68017 D Common Stock 2024-06-17 4 M false 12500 6.09 A 80517 D Common Stock 2024-06-17 4 S false 12500 14.46 D 68017 D Common Stock 2024-06-17 4 S false 1404 14.54 D 66613 D Stock Option (Right to Buy) 6.97 2024-06-17 4 M false 1404 6.97 D 2033-03-07 Common Stock 1404 46324 D Stock Option (Right to Buy) 6.09 2024-06-17 4 M false 12500 6.09 D 2033-03-27 Common Stock 12500 37500 D Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. /s/Mark J. Casey, Attorney-in-Fact 2024-06-20